BioHarvest Sciences (NASDAQ:BHST) Given Sell (E+) Rating at Weiss Ratings

Key Points

• BioHarvest Sciences' stock received a "sell (e+)" rating from Weiss Ratings, while Wall Street Zen upgraded the stock to a "hold" rating, reflecting mixed analyst sentiment.
• The company's stock is currently trading at $11.51, down 3.3%, with an average target price of $13.67 based on an average "Moderate Buy" rating.
• In its latest earnings report, BioHarvest Sciences missed EPS expectations, reporting ($0.15) and a revenue of $8.52 million, indicating ongoing financial challenges.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report)'s stock had its "sell (e+)" rating reissued by investment analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

Separately, Wall Street Zen raised shares of BioHarvest Sciences to a "hold" rating in a research note on Saturday, October 18th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BioHarvest Sciences has an average rating of "Moderate Buy" and an average target price of $13.67.

BioHarvest Sciences Trading Down 3.3%

BHST stock traded down $0.39 on Friday, hitting $11.51. The company's stock had a trading volume of 41,592 shares, compared to its average volume of 28,185. The firm has a 50 day moving average of $9.61 and a two-hundred day moving average of $7.78. BioHarvest Sciences has a 1 year low of $4.66 and a 1 year high of $12.80. The stock has a market cap of $189.05 million, a price-to-earnings ratio of -16.44 and a beta of 0.78.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.04). BioHarvest Sciences had a negative net margin of 39.95% and a negative return on equity of 11,357.84%. The business had revenue of $8.52 million during the quarter, compared to analysts' expectations of $8.53 million. BioHarvest Sciences has set its Q3 2025 guidance at EPS. As a group, equities analysts forecast that BioHarvest Sciences will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On BioHarvest Sciences

An institutional investor recently raised its position in BioHarvest Sciences stock. True North Advisors LLC boosted its holdings in BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) by 7.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 44,391 shares of the company's stock after acquiring an additional 3,120 shares during the period. True North Advisors LLC owned 0.27% of BioHarvest Sciences worth $275,000 as of its most recent filing with the Securities and Exchange Commission.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.